Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck
Autor: | Yoshiyuki Iida, Takanori Kawabata, Tomoya Yokota, Hirofumi Ogawa, Takashi Mukaigawa, Yusuke Onozawa, Tsuyoshi Onoe, Satoshi Hamauchi, Hirofumi Yasui, Ari Nishimura, Hiromichi Shirasu |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Prognostic factor Metastasis 03 medical and health sciences 0302 clinical medicine Surgical oncology Internal medicine medicine Humans Head and neck Retrospective Studies Cetuximab Squamous Cell Carcinoma of Head and Neck business.industry Hazard ratio Hematology General Medicine Prognosis medicine.disease Confidence interval Locoregional disease 030104 developmental biology Head and Neck Neoplasms 030220 oncology & carcinogenesis Surgery Neoplasm Recurrence Local business medicine.drug |
Zdroj: | International Journal of Clinical Oncology. 26:1822-1830 |
ISSN: | 1437-7772 1341-9625 |
Popis: | Distant metastasis is a poor prognostic factor in recurrent/metastatic squamous cell carcinoma of the head and neck. However, limited information on the prognostic impact of locoregional disease is available, despite its life-threatening features. We investigated the prognostic impact of incurable locoregional disease and distant metastasis in recurrent/metastatic squamous cell carcinoma of the head and neck. We retrospectively analyzed 156 patients with recurrent/metastatic squamous cell carcinoma of the head and neck who received palliative chemotherapy between August 2006 and December 2019. The median follow-up time for all censored patients was 12.1 (range 1.9–63.5) months. The median overall survival was 12.4 (95% confidence interval 10.1–15.1) months. Incurable locoregional disease (hazard ratio: 2.31, P = 0.007), liver metastasis (hazard ratio: 2.84, P = 0.006), disease-free interval > 13 months (hazard ratio: 0.51, P = 0.041), cetuximab use (hazard ratio: 0.59, P = 0.007), and immune checkpoint inhibitor use (hazard ratio: 0.56, P = 0.006) were associated with prognosis. The number of distant metastatic sites was not associated with overall survival (1–2: hazard ratio: 0.60, P = 0.16; 3–4: hazard ratio: 1.34, P = 0.50). Patients with incurable locoregional disease had more life-threatening events than those with curable locoregional disease. The presence of incurable locoregional disease had a significant prognostic impact, whereas the number of distant metastatic sites had no prognostic impact. Liver metastasis was a poor prognostic factor for recurrent/metastatic squamous cell carcinoma of the head and neck. |
Databáze: | OpenAIRE |
Externí odkaz: |